Title:

PLK1 targets NOTCH1 during DNA damage and mitotic progression.

Authors
Carlo De Blasio¹#, Azzurra Zonfrilli¹, Matteo Franchitto¹, Germano Mariano¹, Samantha Cialfi¹, Nagendra Verma¹, Saula Checquolo², Diana Bellavia¹, Rocco Palermo¹, Dario Benelli¹, Isabella Screpanti¹ and Claudio Talora¹*

¹Department of Molecular Medicine; Sapienza University of Rome; Rome, Italy; Rome, Italy; ²Department of Medico-Surgical Sciences and Biotechnology, Sapienza University, Latina, Italy; # Present address: INSERM-Montpellier Cancer Center France

Contact Information: C. Talora, Sapienza University of Rome, Viale Regina Elena 291 00161 Rome ITALY E-mail: claudio.talora@uniroma1.it

Carlo De Blasio & Azzurra Zonfrilli equally contributed to this manuscript

Running Title: Molecular mechanism of Notch1 duality

Key words: NOTCH1; PLK1; DNA-Damage

Page Footnotes: 7 figures; 6 supplementary figures; 1 supplementary Table.
Abstract

Notch signaling plays a complex role in carcinogenesis and its signaling pathway has both tumor-suppressor and oncogenic components. To identify regulators that might control this dual activity of NOTCH1, we screened a chemical library targeting kinases and identified Polo-like kinase 1 (PLK1) as one of the kinases involved in Arsenite-induced NOTCH1 down-modulation. As PLK1 activity drives mitotic entry but also is inhibited after DNA damage, we investigated the PLK1-NOTCH1 interplay in the G2 phase of the cell cycle and in response to DNA damage. Here, we found that PLK1 regulates NOTCH1 expression at G2/M transition. However, when cells in G2 phase are challenged with DNA damage PLK1 is inhibited to prevent entry into mitosis. Interestingly, we found that the interaction between NOTCH1 and PLK1 is functionally important during the DNA damage response (DDR), as we found that whereas PLK1 activity is inhibited NOTCH1 expression is maintained during DDR. During genotoxic stress, cellular transformation requires that pro-mitotic activity must override DNA damage checkpoint signaling to drive proliferation. Interestingly, we found that Arsenite-induced genotoxic stress causes a PLK1-dependent signaling response that antagonizes the involvement of NOTCH1 in the DNA damage checkpoint. Taken together, our data provide evidence that Notch signaling is altered but not abolished in SCC cells. Thus, it is also important to recognize that Notch plasticity might be modulated and could represent a key determinant to switch on/off either the oncogenic or tumor suppressor function of Notch signaling in a single type of tumor.
**Introduction**

*NOTCH* signaling is essential for development and it is a type of cell-cell signaling that participates in a wide range of biological processes from neurodegeneration to tumorigenesis (1,2). The canonical *NOTCH* pathway is mediated by the regulated intramembrane proteolysis pathway, in which *NOTCH* receptors undergo ligand-dependent sequential endoproteolysis via different enzymes, including PS/y-secretase (3). The NOTCH-1 ICD (NICD), which is produced by PS/y-secretase-mediated cleavage at site 3 (S3) within the trans-membrane domain, translocates to the nucleus to active transcription of target genes (1,2). Alteration of *NOTCH* signaling has been described as a major player in several human cancers (4). Furthermore, multiple lines of evidence indicate that *NOTCH* signaling is not exclusively oncogenic but can act as a tumor suppressor. In animal models, evidence for *NOTCH* signaling in mediating each of these roles has been established. Additionally, the NOTCH1 tumor suppressor role is also underlined by the loss or inactivating mutations of members of the *NOTCH* signaling pathway in human cancers, particularly in head and neck squamous cell carcinoma (HNSCC) in which inactivating mutations of *NOTCH1* were found in 10–15% of the tumors (5-10). Interestingly, a subset of HNSCC tumors with *NOTCH1* wild-type sequence exhibit *NOTCH* pathway copy number increase with activation of the downstream *NOTCH* targets, *HES1/HEY1*(5,10). Additionally, inhibition of *NOTCH1* or *HEY1* significantly decreased cell growth of primary tumor-derived cells indicating their potential involvement in HNSCC development (5,10,11). The molecular regulation of the dichotomous function of *NOTCH* signaling remains poorly understood. For this reason, we studied this dual activity of *NOTCH1* in Arsenic-induced keratinocyte transformation thus providing a model to investigate the molecular aspects determining whether *NOTCH* signaling will be either oncogenic or tumor suppressive (12). We observed that the mechanism is characterized by two phases, the first phase involves the down modulation of NOTCH1 expression and the second phase involves the acquisition of resistance to Arsenite-induced downregulation of NOTCH1 (12). We found that maintenance of NOTCH1 expression supports metabolic activities to enhance cytoprotection against oxidative-stress that as a side effect may sustain cell proliferation and keratinocyte transformation, strengthening the hypothesis that tumor cell selection could favor
partial rather than complete inactivation of this signaling pathway (12). To identify regulators that may influence the dichotomous NOTCH1 function, we screened a chemical library targeting human kinases and identified Polo-Like kinase 1 (PLK1) as one of the kinase involved in Arsenite-induced down modulation of NOTCH1 expression. The Polo Like Kinase is an important regulator of cell division responsible for a wide number of functions: centrosome maturation, DNA replication, mitotic entry and adaptation to persistent DNA damage (13,14). We identified NOTCH1 as a novel direct target of PLK1 kinase activity. PLK1 inhibition reduced Arsenite-induced NOTCH1 down modulation. Arsenic is known to have genotoxic and mutagenic effects; genotoxic stress causes proliferating cells to activate the DNA damage checkpoint to assist DNA damage recovery by slowing cell cycle progression. Thus, to drive proliferation and transformation, cells must tolerate DNA damage and suppress the checkpoint response ((15) and reference there in). We report here that PLK1 promotes NOTCH1 down modulation to the G2-M transition; conversely NOTCH1 remains active during a DNA damage-induced G2 arrest. Our data show that NOTCH1 plays pleiotropic effects in DNA damage-arrested cells and also in those contexts where NOTCH1 is known to play a tumor suppressor function, cancer cells might still be dependent on specific NOTCH1 signals to sustain their cancerous phenotype.

Results

PLK1 as a central kinase involved in Arsenite-induced NOTCH1 down-modulation.

To explore the mechanisms that determine whether NOTCH signaling will be either oncogenic or tumor suppressive we used a well-defined in vitro model in which the non-tumorigenic human keratinocyte cell line (HaCaT) was acutely exposed to arsenic-trioxide (Arsenite). We previously demonstrated that loss of FBXW7 induction might contribute to acquire both resistance to Arsenite-induced downmodulation of NOTCH1 and HaCaT transformation (12). Here we show that Arsenite stimulates the serine phosphorylation of NOTCH1 with the parallel decreased expression of NOTCH1 and upregulation of FBXW7 levels (Fig.1, A-B-C). Treatment of cells with the proteasome inhibitors prevented the decrease of NOTCH1
expression (Fig.1, A-B). FBXW7 is a constituent of the SCF ubiquitin ligase complex (SKP1-CUL1-F box) that controls the degradation of NOTCH1. Substrate phosphorylation is required for FBXW7-mediated recognition (16-18). Thus, we developed a luciferase assay to identify the kinase that would prime NOTCH1 for recognition by FBXW7. First, HaCaT cells were transiently transfected with an expression vector of NOTCH1-IC. At 36 hrs after transfection, the cells were treated with Arsenite for the last 12 hrs at the indicated concentrations (1-5-10 µM). Total cell lysates were collected and subjected to western blot analysis. Arsenite treatment decreased the NOTCH1 level compared with the vehicle-treated control cells (Fig.1, D) indicating that exogenous NOTCH1-IC is degraded similarly to the endogenous NOTCH1. Then, we used a 12xCSL-luciferase reporter vector responsive to NOTCH1 signaling and we found that NOTCH1 transcriptional activity was strongly suppressed by Arsenite treatment (Fig.1, D-right panel). This functional assay was used to screen a kinase inhibitor library of 378 small-molecule compounds. All compounds were screened in triplicate at 10µM in the presence of 5 µM Arsenite (data not shown). Those compounds showing at least a >50% recovery of luciferase activity were further tested by luciferase assay and western blot (Fig.S1 and S2). We identified 27 kinases able to rescue the NOTCH1 luciferase activity (Fig.S1). To understand the functional context of how the identified kinases might have an impact on NOTCH1, we performed a network analysis in which we investigated all possible direct and indirect interactions among them. For this purpose, the full Pathway-Commons database of reported protein interactions in Simple Interaction Format (SIF) was performed. This analysis resulted in a network comprising 611 proteins with 2263 interactions (Fig. S3). The central component of the shortest path network was the protein PLK1. PLK1 is a pro-mitotic kinase, and its main function is to facilitate the mitotic process (13,14). However, PLK1 also promotes cell cycle progression in cells under stress conditions, thus facilitating tolerance to genotoxic stress (15). Arsenic is known to have genotoxic and mutagenic effects and we observed that Arsenite treated cells were arrested in G2 ((12) and Fig.2, A). Thus, we tested whether PLK1 activity might affect NOTCH1 expression following Arsenite treatment. PLK1 activation requires phosphorylation on a conserved threonine in the T-loop of the kinase domain (T210). PLK1 is first phosphorylated on T210 in G2 phase by the kinase Aurora-A, in concert with its cofactor Bora (19,20). Thus, to further characterize the pattern of
T210 phosphorylation and NOTCH1 stability, HaCaT cells were treated with Arsenite and cultured in the presence or absence of both PLK1 and Aurora inhibitors. In agreement with the luciferase assay, accumulation of NOTCH1 protein upon PLK1-inhibitors treatment was observed in Arsenite untreated and treated HaCaT cultures as well as in SCC022, squamous cell carcinoma derived cell line (Fig.2, B-D-E). We previously demonstrated that Arsenite-transformed keratinocytes acquire resistance to Arsenite-induced NOTCH1 down modulation. Here, we observed PLK1 activation and NOTCH1 down-regulation after Arsenite treatment in the presence of DNA damage signals, as shown by increased γ-H2AX (Supplementary Figure. S5). We also found that PLK1 activation was not observed in Arsenite-transformed keratinocytes (HaCaT-R) after Arsenite treatment (Fig.2, F). This indicates that PLK1 activity might play a potential contribution at the early stages of Arsenite carcinogenesis and that in Arsenite-transformed keratinocytes PLK1 is not longer required in response to Arsenite-treatment, as cells have acquired a molecular switch required for cellular adaptation to genotoxic-stress, (e.g metabolic adaptation) (12).

**NOTCH1 is a direct target of PLK1.**

Analysis of the NOTCH1 C-terminal primary amino acid sequence by different computational platforms revealed the presence of multiple potential phosphorylation sites for the PLK1 consensus sequences (RXX[pS/pT]XRXXR). However, to narrow down the number of candidate motifs prior to experimental verification we analysed the NOTCH1 protein sequence by considering as putative candidate motifs only those identified via a high-stringency analysis and that can be recognized by both PhoshoNET and GPS-Polo 1.0 platforms. Two sites S1791 and S2349 were identified by these criteria (Supplemental Fig.4, A-B-C). Interestingly, both motifs are conserved across species and S1791 was found to be phosphorylated also in colon cancer cells (21). To confirm that NOTCH1 can be phosphorylated by PLK1, we performed an in vitro kinase assay using purified recombinant PLK1 and NOTCH1-IC fragment as substrate. As shown Fig.S4, D, the C-terminal NOTCH1 fragment was readily phosphorylated by PLK1. Additionally, when the two putative phosphorylation sites, S1791 and S2349 were replaced by Ala wild-type NOTCH1-IC but not the mutant was efficiently phosphorylated (Fig. S4, E).

To test whether the phosphorylation of NOTCH1-IC on the putative PLK1
phosphorylation sites determined the stability of NOTCH1-ICD cells expressing either wild-type NOTCH1-IC or mutants NOTCH1-IC-A1791/A2349 constructs were treated with Cycloheximide. At various time points thereafter, the transfected cells were lysed and the amounts of the NOTCH1 proteins were measured by Western blot analysis. We found that mutation of Ser 1791/2349 promotes NOTCH1-IC stabilization (Fig. S4, F).

**NOTCH1 is a Substrate of PLK1 in the G2 phase of the Cell Cycle.**

To understand the functional significance of PLK1-mediated regulation of NOTCH1 we focused our attention to the PLK1/NOTCH1 expression during cell cycle. It is well known that in G2, PLK1 is activated to promote entry into mitosis (14 and reference there in). Thus, we sought to find the physiological conditions required to degrade NOTCH1 in the cell cycle context. To this purpose, we conducted synchronization experiments in HaCaT and SCCO22 human cells. A Hydroxyurea block and release was performed to synchronize the cells in G1/S and the cell cycle profile was monitored. After the cells were released from the Hydroxyurea-induced G1/S block, the cells were harvested and subjected to a Western blotting analysis. The phosphorylation of Thr210 was observed strongly at the G2 phase of the cell cycle, a pattern inversely correlated with the NOTCH1 expression (Fig. 3, A-B). However, the inhibition of PLK1 by BI2536 induced the accumulation of NOTCH1 protein (Fig.3, C), confirming that PLK1 promotes NOTCH1 down modulation during the cell cycle. Our data indicate that PLK1 phosphorylates and consequently destabilizes NOTCH1 in the G2-M transition. However, in order to be transformed, in cells under genotoxic stress the checkpoint response should be down-regulated to tolerate the cellular DNA damage stresses. PLK1 activation regulates the checkpoint activation and allows cells to grow under genotoxic stress (22). Moreover, PLK1 is also known to be involved in promoting resistance to chemotherapeutic regimens with drugs such as doxorubicin (a DNA intercalating compound) (23). We found that under arsenite treatment NOTCH1 is continuously degraded and in this condition PLK1 is active (Fig. 1 and 2). Notably, a G2 phase-specific inactivation of PLK1 after DNA damage has been described, the reason for this inactivation is to promote cell cycle exit in order to avoid proliferation and entry in mitosis in the presence of damaged DNA. Thus, we investigated whether PLK1 targets NOTCH1 during G2 in response to DNA damage. To this end, both
HaCaT and SCCO22 cells were synchronized at G1/S and then allowed to progress through the cell cycle. At 7 hr after the release from G1/S (when cells were in G2), cells were pulsed with Doxorubicin for 1 hr to induce DNA damage and harvested 18 hrs after Doxorubicin release (Fig.4, A only HaCaT cells are shown). As expected, induction of DNA damage results in decreased levels of PLK1 and activation of ATM (Fig. 4, B-C). Notably, when PLK1 was dephosphorylated and inactive, the expression of NOTCH1 was restored indicating that NOTCH1 expression is up-regulated during G2-Damage checkpoint (Fig.4, B-C). Interestingly, similar results were obtained in FaDu cells, a SCC cell line with mutated p53, and HeLa cells, an adenocarcinoma cell line with WT p53, (Fig. S6), strengthening the argument that NOTCH1 and PLK1 are inversely correlated during DNA damage response.

Upon DNA Damage in G2, NOTCH1 Protects cells from apoptosis.

To unravel how PLK1 and NOTCH1 might functionally interact, we investigated whether NOTCH1 had a mitotic role. To this end, we made use of Ser 1791/2349 mutant NOTCH1-IC. SCCO22 cells were transfected with either empty vector or NOTCH1-IC Ser 1791/2349 mutant. Cells were synchronized at the G1/S and released into the cell cycle; we didn’t observe any difference in cell cycle progression as phosphorylated Histone H3 (p-H3) showed the same kinetic during release (Fig. 5 A) in both control and NOTCH1-IC Ser 1791/2349 mutant treated cells. Furthermore, no mitotic delay was detected in cells examined at either early time (1 and 2h) or at longer time after Nocodazole release (Fig. 5 B and data not show). We conclude that in this cellular context NOTCH1 does not alter the G2/M transition. Previous observations established that PLK1 plays a critical role in the G2 checkpoint recovery following DNA damage (14,24), and we found that NOTCH1 expression is upregulated during G2-Damage checkpoint (Fig.4). Thus, we evaluated whether NOTCH1 expression would alter recovery following DNA damage. To test this, cells were synchronized at the G1/S and released into the cell cycle; after 6 hrs from release cells were treated with Doxorubicin to induce G2 damage checkpoint. Later cells were treated with caffeine to abrogate G2 checkpoint response. As expected, we detected an increase of phosphorylated Histone H3 (pH3) in empty vector treated cells after Caffeine addition (Fig. 5 C). Interestingly, NOTCH1-IC mut expression
enhanced pH3 expression (Fig. 5 C). Treatment of cells with Caffeine abrogate G2
checkpoint but also promotes mitotic catastrophe and apoptosis (14). Consistently, we
found that in empty-vector treated cells Caffeine treatment induced caspase-3
activation, whose expression levels were reduced in NOTCH-IC mut treated cells
(Fig. 5 D). Although, we observed a differential expression of the cleaved caspase-3
neither empty nor NOTCH1-IC mutant treated cells showed sign of apoptosis after
caffeine addition (data not shown). The mechanism by which DNA-damaged cells
escape from apoptosis during DNA-damage checkpoint is poorly understood.
Therefore, we wondered whether the requirement of NOTCH1 during DNA-damage
induced G2 checkpoint could be restricted to such an anti-apoptotic signaling. To test
this, we designed an experimental set-up to examine if a cell cycle arrest/restart
following a DNA damage-induced G2 arrest in HaCaT cells would be dependent on
the function of NOTCH1. HaCaT immortalized cells were chosen because in this
cellular context, conversely to SCCO22 cells, sustained DNA damage checkpoint
promotes apoptosis. Thus, HaCaT cells released from a Hydroxyurea block were
treated with doxorubicin at 7 hrs after release, a time at which the great majority of
the cells had completed S-phase (Fig. 6 A). Using this approach we were able to
obtain a highly synchronous population of cells arrested at the G2 DNA damage
checkpoint by Doxorubicin (Fig. 6 A). Subsequently, we mimicked checkpoint
silencing by addition of the checkpoint kinase inhibitor Caffeine and allowed the cells
to enter mitosis in the presence of Nocodazole. Notably, Doxorubicin treatment of
HaCaT cells resulted in lower mitotic index when compared to control cells (Fig. 6 A
lower panels, diagram 3-4). After 3-6 hrs of Caffeine treatment a significant fraction
of cells entered mitosis as judged from phospho-Histone H3 staining (Fig. 6 A lower
panels). When cells entering in the G2-damage induced checkpoint were examined in
more detail, a decrease in pPLK1 level and the appearance of NOTCH1 expression
were observed (Fig. 6 B lane 3-4). When we analyzed cell recovery from DNA
damage induced arrest after doxorubicin treatment, we found that G2-arrested cells
could be forced to enter mitosis following addition of Caffeine. Interestingly, Caffeine
treatment increased PLK1 expression, indicating that as previously shown PLK1
becomes essential for mitotic entry and recovery from a DNA damage-induced G2
arrest (24). Consistent with a role for PLK1 in the control of NOTCH1 expression, we
found that pPLK1 activation was paralleled by NOTCH1 downmodulation when
Caffeine was added to induce recovery from a DNA damage-induced G2 arrest (Fig 6 B). Notably, NOTCH1 does not seem to be instrumental for achieving a DNA damage-induced arrest, since GSI-treated cells efficiently arrested in response to DNA damage (Fig. 6, A-7th diagram). Strikingly, when we examined the fate of the damaged cells that are in the DNA damage-induced G2 arrest or induced to enter mitosis by the addition of Caffeine in the presence of GSI, we found that cell viability was severely affected (Fig. 6 C). These results demonstrate that NOTCH1 protects cells from DNA damage-induced arrest and that PLK1-mediated degradation of NOTCH1 may be essential for recovery from a DNA damage-induced arrest.

**NOTCH1 promotes inflammatory cytokine secretion in cancer cells that undergo growth-arrest in response to DNA damage.**

Induction of cell cycle arrest in response to DNA-damage represents a protective mechanism against harmful mutations but also promotes apoptosis (14,24). We found that NOTCH signaling protects immortalized HaCaT cells from DNA damage-induced apoptosis. Conversely, we observed that in the squamous cell carcinoma cell line, SCCO22, induction of DNA damage by doxorubicin treatment promotes a permanent cell cycle arrest with no sign of apoptosis (Fig. 7 and data not shown). In response to DNA damage, growth-arrested cancer cells also develop a secretory phenotype that alters tissue microenvironments and might stimulate tumor growth in vivo (25). Among the secreted factors, IL-6 and IL-8 are of particular interest. These cytokines have been shown to promote tumorigenesis by regulating processes associated with tumorigenesis ranging from cancer metabolism to metastasis (25,26). Therefore, we wondered whether NOTCH1 during DNA-damage induced G2 checkpoint could be involved in such secretory signaling. To test this, SCCO22 cells were treated with Doxorubicin to induce G2 damage checkpoint (Fig. 7 A). Later cells were treated with GSI to inhibit NOCTH signaling (Fig.7, B-C). As expected, we detected an increase of IL-6 and IL-8 in Doxorubicin treated cells (Fig. 7 C). Interestingly, GSI treatment decreased both IL-6 and IL-8 expression (Fig. 7 C), but not TGFB1 that has been associated with the development of a secretory phenotype of cancer cells. Thus, these data support a model in which the epithelia cancer cells, SCCO22, use Notch signaling to support a secretory phenotype.
Discussion

NOTCH1 activity plays pivotal roles in signaling for diverse cellular processes, such as cell differentiation, stem cell renewal, proliferation and transformation (1,8,27). NOTCH1 signaling has been reported to have a contradictory role in cell transformation (4,8). However, a widely accepted model implies that the impact of NOTCH1 signaling is highly context dependent and it can have opposite effects in different systems. We have used Arsenite-induced malignant transformation of a human epithelial cell line as an in vitro model to study the mechanisms that can result in NOTCH1 role and function alterations (12). We previously demonstrated that whereas Arsenite-mediated apoptosis of immortalized keratinocytes was associated with NOTCH1 down-regulation, Arsenite-mediated transformation of these cells was characterized by increased NOTCH1 stability (12). We found that NOTCH1 regulates cellular metabolism and apoptosis, which in turn differentially impact cell proliferation and cell transformation (12). Consequently the cellular genetic/context may impinge on the antagonistic duality of NOTCH1 function. We presented evidence indicating that FBXW7 is required for the differential expression of NOTCH1 during Arsenite-mediated transformation; indicating that kinases and biochemical pathways could be involved in NOTCH1 phosphorylation in tumors. Given that NOTCH1 stability and signaling are controlled by its phosphorylation (21), the study of kinases that could be implicated in this post-translational modification could help to elucidate the mechanisms controlling NOTCH1 dichotomy in cancer development. In this study, the effects of 378 cellular kinase inhibitors on NOTCH1 transcriptional activity and protein stability after Arsenite-treatment were investigated. Our findings indicate that multiple kinases implicated in various cell signaling pathways can participate in these outcomes: FAK, IKKB, PKA, ATM, ATR, SRC, p38, m-TOR, GSK1, c-MET, CDK1, ALK, PLK1, AURKA/B, CSF1R VEGFR and JAK. To understand how the identified kinases might have an impact on NOTCH1, we performed a network analysis to investigate all possible direct and indirect interactions among them. The central component of the shortest path network was the protein PLK1, which is a central regulator of cell division required for several events of mitosis and cytokinesis (13,14). Whereas in non-damaged cells PLK1 pathways is involved in G2/M
transition, PLK1 was shown to be a direct target of the G2 DNA damage checkpoint. Indeed in response to a wide range of DNA-damaging agents, PLK1 was shown to be catalytically inactivated. Moreover, this inhibition was shown to depend on functional ATM or ATR (14). Such control of the cell cycle machinery may be critically important to prevent a premature restart of the cell cycle following genotoxic stress. However, in addition to being a target of the DNA damage checkpoint, PLK1 was also shown to regulate cell cycle progression after a damage-induced cell cycle arrest. In this context cells escape the DNA damage checkpoint arrest in a process called ‘adaptation’. Such a mechanism allows damaged cells to eventually divide and possibly survive and undergo transformation (14,15). Consistent with the above observation we found that when challenged with Arsenite, cells were G2-arrested. The data presented here show that NOTCH1 is a novel substrate of PLK1. Additionally, we found that in an unperturbed cell cycle, PLK1 appears to be involved in NOTCH1 down-modulation at the mitotic entry. Interestingly, we observed an increase in the levels of T210-PLK1 expression, which indicates that PLK1 by facilitating tolerance to Arsenite-induced genotoxic stress might favor Arsenite-induce cell transformation. Notably, the coordination of this pathway becomes critical for both DNA-Damage checkpoint and mitotic entry in cells recovering from a DNA damage-induced arrest (28). Although its exact involvement remains to be established, in Arsenite-induced transformation NOTCH1 represents a checkpoint mediator targeted by PLK1 in order to silence the DNA-damage checkpoint in a condition in which damage persists for long periods of time. Thus, PLK1 activation initiates an escape program from checkpoint-mediated arrest prior completion of damage repair. NOTCH1 inactivation is part of the PLK1-associated adaptation program to DNA Damage that can result in enhanced cell death (e.g through mitotic catastrophe) but at the same time may allow the propagation of defects in the genome to the daughter cells that may contribute to cell transformation. Although, our observations necessitate further analysis to understand how deregulation of NOTCH1 pathway impacts on signaling that respond to DNA damage, we provide evidence that Notch signaling is altered but not abolished in SCC cells. We found that NOTCH signaling might contribute to the secretory phenotype of epithelial cancer cells. Thus, the dual role of Notch in cancer biology is undoubtedly complex and tumor type-
independent. It is important to recognize that even in a single type of tumor, there is plasticity in Notch function that deserves greater attention.
Experimental procedures

Cell culture and transfection

HaCaT-S immortalized and HaCaT-R cells were previously described (12). Culture cells 70–80% confluent were maintained in modified low calcium medium and transfected using the Lipofectamine transfection Reagent (L-006119-00; Thermo Scientific/Dharmacon, Lafayette, CO, U.S.A.) according to manufacturer’s instructions (Thermo Fisher Scientific, MA USA). Cells were analyzed at the indicated times after transfection by either RT-PCR analysis or Western blot as indicated (12,29). SCCO22 were kindly provided by Dr. Caterina Missero, Università degli Studi di Napoli, Naples Italy. HeLA and FaDu were kindly provided by Dr. Angelo Peschiaroli, CNR, Rome, Italy.

Reagents and immunoblotting

The following reagents were purchased from Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A: Fbxw7, Tubulin. In addition we used Notch1 Val1744, Notch1 D1E11, PLK1 208G4, PLK1(Tr210), from Cell Signaling Technology (Beverly, MA, U.S.A). gamma-secretase inhibitor IX (DAPT), was purchased from Calbiochem (Merck KGaA), dissolved in dimethyl sulfoxide (DMSO) and stored at -20 until use. All cell extracts were prepared as previously described (30) and according to the manufacturer’s instructions for detection of phosphor-ERK (Cell Signaling Technology, Beverly, MA, U.S.A.). The kinase library of 378 structurally diverse, cell permeable kinase inhibitors was purchased from Selleckchem (Houston, TX, USA; catalog No. L1200) (supplementary information Table 1).

Notch1-ICD encodes the expression of human Notch1-IC from aa 1757 to aa 2555 and has been previously described in (9). GST-NOTCH1-IC plasmid encodes the GST-Notch1-IC fusion protein encoding the mouse NOTCH1-IC region 1753-2531 was kindly provided by Dr. Lendhal, Karolinska Institute Stockholm, Sweden and previously described in (31). The plasmids containing mutations in Notch1-ICD encoding the expression of human Notch1-IC from aa 1757 to aa 2555 were generated using QuikChange II XL Site-Directed Mutagenesis kit (Thermo Fisher Scientific, MA USA) and verified by sequencing.
Kinase library screening.

Transient transfection/promoter activity assays were performed using a Dual-Luciferase/Renella Reporter Assay System (Promega). All conditions were tested in triplicate samples. A 12xCSL-luciferase reporter vector responsive to NOTCH signaling was co-transfected with either pcDNA3 as control or NOTCH1-IC vector. At 24 hr after transfection cells were treated with compounds in triplicate at 10μM and luciferase assay determined in the presence of 5 μM Arsenite. The results were normalized against Renilla-luciferase. To control for cytotoxic effect of the compounds when the Renilla luciferase activity was reduced to < 25% of the activity seen with the vehicle-treated controls and survival rate was less than 75%, those compounds were excluded from further analysis. Those, compounds showing at least a >50% recovery of luciferase activity were further tested in increasing amount. In this second step each compound was tested in increasing amount, 1, 5, 10 μM in the presence of 5 μM Arsenite. All compounds were further tested for their ability to rescue NOTCH1 expression after Arsenite treatment by western blot at 10μM in the presence/absence of 5 μM Arsenite.

PLK1 kinase assay

For PLK1 kinase assay GST-Nocth1 fusion protein was expressed in E. Coli BL21 strain and purified using standard procedure. PLK1 kinase assays were carried out using PLK1 activity assay reagent Kit purchased form SignalChem (Richmond, BC Canada) according to the manufacturer's instructions.

Cell-Cycle Analysis

To analyze mitotic entry, cells were fixed and stained with propidium iodide and an antibody against phospho-Histone H3 (Ser10) using FlowCellect™ Cell Cycle Kit for G2/M Analysis (EMD Millipore, Darmstadt, Germany). The percentages of M phase cells and cellular DNA content were determined by flow cytometry using a FACSCalibur flow-cytometer (BD Biosciences).

Synchronization, and Recovery from DNA Damage. HaCaT, SCCO22, FaDu and HeLa cells were grown in DMEM and RPMI supplemented with 10% FCS, 100 U/ml penicillin, and 100 μg/ml streptomycin. For the synchronization experiments cells
were incubated in Hydroxiurea (1.5 mM) for 19 hr to arrest cells at the G1/S transition. Where indicated, the G2/M DNA damage checkpoint was activated by treating cells with 0.5 μM Doxorubicin for 1 hr at 7 hrs after release from a hydroxyurea block. Doxorubicin was washed away thoroughly and immediately after washing, Nocodazol (250ng/ml) was added to the culture medium. At 18 hrs after washing away Doxorubicin, all cells were arrested in G2 as judged from FACS analysis. In order to inactivate DNA damage signaling and allow mitotic entry, Caffeine (5 mM) was added to inhibit ATR and ATM checkpoint kinases. The continuous presence of Nocodazole prevented exit from mitosis and allowed accumulation of cells in mitosis. In order to inactivate NOTCH1 signaling, GSI (5μM) was added 30 min before Doxorubicin treatment and then maintained until cells were harvested for further analysis.

Acknowledgments
This work was supported by the Italian Association for Cancer Research (AIRC) IG-15218. PRIN-2017XCXAFZ. Sapienza-Progetti Ateneo 2017.

Conflict of Interest
The authors declare that they have no conflicts of interest with the contents of this article.

Author Contributions
CT designed the research, analyzed the data and wrote the paper; CDB, AZ, GM, MF, NV, SC, DB, CT performed experiments; IS, RP, SC, commented on the paper. CT, GM, CDB, and AZ assembled the figures.
References

1. Artavanis-Tsakonas, S., Rand, M. D., and Lake, R. J. (1999) Notch signaling: cell fate control and signal integration in development. Science 284, 770-776

2. Mumm, J. S., and Kopan, R. (2000) Notch signaling: from the outside in. Dev Biol 228, 151-165

3. De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., Goate, A., and Kopan, R. (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518-522

4. Palermo, R., Checquolo, S., Bellavia, D., Talora, C., and Screpanti, I. (2014) The molecular basis of notch signaling regulation: a complex simplicity. Curr Mol Med 14, 34-44

5. Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T. X., Zhang, J., Wang, J., Zhang, N., El-Naggar, A. K., Jasser, S. A., Weinstein, J. N., Trevino, L., Drummond, J. A., Muzny, D. M., Wu, Y., Wood, L. D., Hruban, R. H., Westra, W. H., Koch, W. M., Califano, J. A., Gibbs, R. A., Sidransky, D., Vogelstein, B., Velculescu, V. E., Papadopoulos, N., Wheeler, D. A., Kinzler, K. W., and Myers, J. N. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157

6. Dotto, G. P. (2008) Notch tumor suppressor function. Oncogene 27, 5115-5123

7. Nicolas, M., Wolfer, A., Raj, K., Kummer, J. A., Mill, P., van Noort, M., Hui, C. C., Clevers, H., Dotto, G. P., and Radtke, F. (2003) Notch1 functions as a tumor suppressor in mouse skin. Nature genetics 33, 416-421

8. Nowell, C. S., and Radtke, F. (2017) Notch as a tumour suppressor. Nat Rev Cancer 17, 145-159

9. Rangarajan, A., Talora, C., Okuyama, R., Nicolas, M., Mammucari, C., Oh, H., Aster, J. C., Krishna, S., Metzger, D., Chambon, P., Miele, L., Aguet, M., Radtke, F., and Dotto, G. P. (2001) Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 20, 3427-3436

10. Wang, N. J., Sanborn, Z., Arnett, K. L., Bayston, L. J., Liao, W., Proby, C. M., Leigh, I. M., Collisson, E. A., Gordon, P. B., Jakkula, L., Pennypacker, S., Zou, Y., Sharma, M., North, J. P., Vemula, S. S., Mauro, T. M., Neuhaus, I. M., Leboit, P. E., Hur, J. S., Park, K., Huh, N., Kwok, P. Y., Arron, S. T., Massion, P. P., Bale, A. E., Haussler, D., Cleaver, J. E., Gray, J. W., Spellman, P. T., South, A. P., Aster, J. C., Blacklow, S. C., and Cho, R. J. (2011) Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A 108, 17761-17766

11. Sun, W., Gaykalova, D. A., Ochs, M. F., Mambo, E., Arnaoutakis, D., Liu, Y., Loyo, M., Agrawal, N., Howard, J., Li, R., Ahn, S., Fertig, E., Sidransky, D., Houghton, J., Buddavarapu, K., Sanford, T., Choudhary, A., Darden, W., Adai, A., Latham, G., Bishop, J., Sharma, R., Westra, W.
18.

H., Hennessey, P., Chung, C. H., and Califano, J. A. (2014) Activation of the NOTCH pathway in head and neck cancer. *Cancer Res* 74, 1091-1104

12. Cialfi, S., Palermo, R., Manca, S., De Blasio, C., Vargas Romero, P., Checquolo, S., Bellavia, D., Uccelletti, D., Saliola, M., D'Alessandro, A., Zolla, L., Gulino, A., Screpanti, I., and Talora, C. (2014) Loss of Notch1-dependent p21(Waf1/Cip1) expression influences the Notch1 outcome in tumorigenesis. *Cell cycle* 13, 2046-2055

13. Archambault, V., Lepine, G., and Kachaner, D. (2015) Understanding the Polo Kinase machine. *Oncogene* 34, 4799-4807

14. van Vugt, M. A., and Medema, R. H. (2005) Getting in and out of mitosis with Polo-like kinase-1. *Oncogene* 24, 2844-2859

15. Wakida, T., Ikura, M., Kuriya, K., Ito, S., Shiroiwa, Y., Habu, T., Kawamoto, T., Okumura, K., Ikura, T., and Furuya, K. (2017) The CDK-PLK1 axis targets the DNA damage checkpoint sensor protein RAD9 to promote cell proliferation and tolerance to genotoxic stress. *Elife* 6

16. Davis, R. J., Welcker, M., and Clurman, B. E. (2014) Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. *Cancer cell* 26, 455-464

17. Koepp, D. M., Schaefer, L. K., Ye, X., Keyomarsi, K., Chu, C., Harper, J. W., and Elledge, S. J. (2001) Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. *Science* 294, 173-177

18. Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki, H., Ishida, N., Okumura, F., Nakayama, K., and Nakayama, K. I. (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. *EMBO J* 23, 2116-2125

19. Bruinsma, W., Macurek, L., Freire, R., Lindqvist, A., and Medema, R. H. (2014) Bora and Aurora-A continue to activate Plk1 in mitosis. *Journal of cell science* 127, 801-811

20. Jang, Y. J., Ma, S., Terada, Y., and Erikson, R. L. (2002) Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase. *The Journal of biological chemistry* 277, 44115-44120

21. Borggreve, T., Lauth, M., Zwijsen, A., Huylebroeck, D., Oswald, F., and Giaimo, B. D. (2016) The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFbeta/BMP and hypoxia pathways. *Biochim Biophys Acta* 1863, 303-313

22. Furuya, K., Miyabe, I., Tsutsui, Y., Paderi, F., Kakusho, N., Masai, H., Niki, H., and Carr, A. M. (2010) DDK phosphorylates checkpoint clamp component Rad9 and promotes its release from damaged chromatin. *Mol Cell* 40, 606-618

23. Gutteridge, R. E., Ndiaye, M. A., Liu, X., and Ahmad, N. (2016) Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. *Mol Cancer Ther* 15, 1427-1435

24. van Vugt, M. A., Bras, A., and Medema, R. H. (2004) Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. *Mol Cell* 15, 799-811
25. Rodier, F., Coppe, J. P., Patil, C. K., Hoeijmakers, W. A., Munoz, D. P., Raza, S. R., Freund, A., Campeau, E., Daalos, A. R., and Campisi, J. (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11, 973-979

26. Colombo, M., Mirandola, L., Chiriva-Internati, M., Basile, A., Locati, M., Lesma, E., Chiaramonte, R., and Platonova, N. (2018) Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu. Front Immunol 9, 1823

27. Kopan, R., and Ilagan, M. X. (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216-233

28. Verma, N., Franchitto, M., Zonfrilli, A., Cialfi, S., Palermo, R., and Talora, C. (2019) DNA Damage Stress: Cui Prodest? Int J Mol Sci 20

29. Cialfi, S., Palermo, R., Manca, S., Checquolo, S., Bellavia, D., Pelullo, M., Quaranta, R., Dominici, C., Gulino, A., Screpanti, I., and Talora, C. (2013) Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression. Leukemia 27, 485-488

30. Vargas Romero, P., Cialfi, S., Palermo, R., De Blasio, C., Checquolo, S., Bellavia, D., Chiaretti, S., Foa, R., Amadori, A., Gulino, A., Zardo, G., Talora, C., and Screpanti, I. (2015) The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPalpha. Leukemia 29, 2442-2445

31. Beatus, P., Lundkvist, J., Oberg, C., and Lendahl, U. (1999) The notch 3 intracellular domain represses notch 1-mediated activation through Hairy/Enhancer of split (HES) promoters. Development 126, 3925-3935
Figure Legends,

Figure 1. Decreased NOTCH1 levels in As$_2$O$_3$ treated keratinocytes. (A,B) HaCaT cells were untreated or treated with As$_2$O$_3$ (As). Twenty-four hours (24 hrs) post-treatment, cells were either untreated or treated with MG132/Carfizomib for 5 hrs before collection; immunoblotting was performed with the indicated antibodies. (C) HaCaT cells were treated with As$_2$O$_3$ for 24 hrs before collection cell extract were immunoprecipitated using an antibody against NOTCH1 and immunoblotting was performed with the indicated antibodies. (D) HaCaT cells were transfected with either pCDNA3 or NOTCH1-IC (encoding the human Notch1-IC, 1757-2555). Thirty-six hours (36 h) post-transfection, cells were treated with As$_2$O$_3$ for 24 hrs before collection; immunoblotting was performed with the indicated antibodies. D- right panel, HaCaT cells were co-transfected with the NOTCH responsive promoter 12XCLC and the NOTCH1-IC plasmid then treated with increasing amounts of As$_2$O$_3$ (5 and 10µM) 12 hrs before collection. Average values and SDs were calculated from triplicate samples. *** P< 0.0001.

Figure 2. Effects of PLK1 inhibition in As$_2$O$_3$-treated cells. A) HaCaT cells were treated for 24 hr with the indicated amount of Arsenite, then cells were collected and cell cycle analyzed by FACS. B, C, D) Immortalized HaCaT cells were treated with the indicated amount of As$_2$O$_3$ for 24 hrs; then cells were treated with plus/minus the indicated inhibitors (PLK1 inhibitor- BI2536; ZM447439 Aurora A/B; RO3280 PLK1; for 24 hrs and analyzed by immunoblot with the indicated antibodies. (E) The indicated cell lines were treated with As$_2$O$_3$ for 24 hrs; then cells were treated with plus/minus 10 µM ZM447439 (ZM) for 24 hrs and analyzed by immunoblot with the indicated antibodies. (F) Immortalized (HaCaT-S) and As$_2$O$_3$-transformed HaCaT cells (HaCaT-R) were treated with increasing amount of As$_2$O$_3$ for 24 hrs and analyzed by immunoblot with the indicated antibodies. Shown are the representative results from at least 3 independent experiments.

Figure 3. PLK1-Dependent Degradation of NOTCH1 at the G2-M transition. A,B) HaCaT and SCCO22 cells were collected at the indicated time points after release from G1/S, cell cycle analyzed by FACS (FACS profile is shown only for HaCaT cells) and cell lysates were immunoblotted with antibodies to the indicated
proteins. C) HaCaT cells were treated for 16 hrs with Nocodazole to induce a mitotic block, and BI2536 (PLK1 inhibitor) added 8 hrs before harvesting. Prometaphase cells were then collected by shake-off and cell extracts were analyzed by immunoblotting with antibodies to the indicated proteins. Shown are the representative results from at least 3 independent experiments.

**Figure 4. NOTCH1 expression in G2 DNA Damage Arrest.** A, B, C) HaCaT cells were left untreated (diagram 1) or treated with Hydroxyurea for 19 hrs (Panel A). Alternatively, cells were released from the HU block and either untreated or treated after 7 hrs with Doxorubicin for 1 hr and subsequently grown in the presence of Nocodazole for 18 hrs. Following these treatments, cells were collected at the indicated time-points after release from G1/S, cell cycle analyzed by FACS (FACS profile is shown only for HaCaT cells) and cell lysates were immunoblotted with antibodies against the indicated proteins (B, C). Shown are the representative results from at least 3 independent experiments.

**Figure 5. Overexpression of NOTCH1 mutant unphosphorylatable by PLK1 has not effect on cell cycle progression.** (A) SCCO22 cells were transfected with, either control, empty-PCDNA3 vector, or A1791/A2391-NOTCH1-ICD mutant. The cells were synchronized with Hydroxyurea for 19 hrs. At the indicated time points after release, the cells were harvested and subjected to immunoblotting for the indicated proteins. (B) Cells were treated as described for panel A, except that cells were trapped with Nocodazole for 14 h and then released. At the indicated time points after release, the cells were harvested and analyzed with the indicated antibodies. (C, D) SCCO22 cells were transfected with either control, empty-PCDNA3 vector, or A1791/A2391-NOTCH1-ICD mutant. The cells were synchronized with Hydroxyurea for 19 hrs. Cells were released from the HU block and either untreated or treated after 7 hr with doxorubicin for 1 hr and subsequently grown in the presence of Nocodazol and Caffeine the last 3 and 6 hrs. Cells were harvested and subjected to immunoblotting for the indicated proteins.

**Figure 6. NOTCH1 expression in recovery from a G2 DNA Damage Arrest.** A) HaCaT cells were left untreated or treated with Hydroxyurea (HU) for 19 hrs. Alternatively, cells were released after the HU block and 7 hr after release treated
with Doxorubicin for 1 hr and subsequently grown in the presence of Nocodazole for 18 hrs. Following these treatments, Caffeine was added for indicated time periods to allow recovery from the checkpoint-induced arrest 3 and 6hr before harvesting the cells. DNA content and phospho-Histone H3 positivity were determined. (B) Cells were treated as described under (A) and whole-cell lysate was used for Western blotting with the indicated antibodies (C). Cells were treated as described in A and % of apoptosis was determined by FACS analysis.

Figure 7. NOTCH1-dependent increased expression of IL-6 and IL-8 during DNA-Damage induced growth arrest.
SCCO22 cells were treated with doxorubicin following and then either DMSO or GSI was added and cells maintained in culture for further 24 hrs. In (A) Cells were analyzed by FACS analysis. (B) Cells were treated as described in (A) and whole-cell lysate was used for Western blotting with the indicated antibodies. Additional samples present on the gel were cropped as indicated by dashed lines. In (C) cells were treated as described for panel A and total RNA was used for qRT-PCR with the indicated probe.
Fig. 1
Fig. 2
Fig. 5

A. Western blot analysis of pH3 and Tubulin expression in pCDNA3 and NOTCH1-Mut treated with HU, NOC, and at different Release points (3, 7, 24).

B. Western blot analysis of pH3 and Tubulin expression in pCDNA3 and NOTCH1-Mut treated with NOC at different Release points (1, 2).

C. Western blot analysis of pH3 and Tubulin expression in pCDNA3 and NOTCH1-Mut treated with Caffeine, HU, NOC, and Dox at 3h and 6h.

D. Western blot analysis of Caspase 3, pH3, and Tubulin expression in pCDNA3 and NOTCH1-Mut treated with HU, NOC, and Dox at 3h and 6h.
Fig. 7
PLK1 targets NOTCH1 during DNA damage and mitotic progression.
Carlo De Blasio, Azzurra Zonfrilli, Matteo Franchitto, Germano Mariano, Samantha Cialfi, Nagendra Verma, Saula Checquolo, Diana Bellavia, Rocco Palermo, Dario Benelli, Isabella Screpanti and Claudio Talora

*J. Biol. Chem.* published online October 9, 2019

Access the most updated version of this article at doi: 10.1074/jbc.RA119.009881

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts